Krka d. d (KRK) - Total Assets
Based on the latest financial reports, Krka d. d (KRK) holds total assets worth zł2.97 Billion PLN (≈ $816.73 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Krka d. d for net asset value and shareholders' equity analysis.
Krka d. d - Total Assets Trend (2010–2024)
This chart illustrates how Krka d. d's total assets have evolved over time, based on quarterly financial data.
Krka d. d - Asset Composition Analysis
Current Asset Composition (December 2024)
Krka d. d's total assets of zł2.97 Billion consist of 64.1% current assets and 35.9% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 12.1% |
| Accounts Receivable | zł591.76 Million | 20.8% |
| Inventory | zł601.69 Million | 21.1% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł58.10 Million | 2.0% |
| Goodwill | zł42.64 Million | 1.5% |
Asset Composition Trend (2010–2024)
This chart illustrates how Krka d. d's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KRK stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Krka d. d's current assets represent 64.1% of total assets in 2024, an increase from 43.1% in 2010.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, up from 0.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 27.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 21.1% of total assets.
Krka d. d Competitors by Total Assets
Key competitors of Krka d. d based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Krka d. d - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.91 | 3.82 | 4.00 |
| Quick Ratio | 2.67 | 2.55 | 2.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł1.43 Billion | zł1.33 Billion | zł933.61 Million |
Krka d. d - Advanced Valuation Insights
This section examines the relationship between Krka d. d's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.02 |
| Latest Market Cap to Assets Ratio | 3.02 |
| Asset Growth Rate (YoY) | 3.1% |
| Total Assets | zł2.85 Billion |
| Market Capitalization | $8.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Krka d. d's assets at a significant premium (3.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Krka d. d's assets grew by 3.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Krka d. d (2010–2024)
The table below shows the annual total assets of Krka d. d from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł2.85 Billion ≈ $784.09 Million |
+3.07% |
| 2023-12-31 | zł2.76 Billion ≈ $760.77 Million |
+2.86% |
| 2022-12-31 | zł2.69 Billion ≈ $739.64 Million |
+5.90% |
| 2021-12-31 | zł2.54 Billion ≈ $698.41 Million |
+13.52% |
| 2020-12-31 | zł2.24 Billion ≈ $615.25 Million |
+2.33% |
| 2019-12-31 | zł2.18 Billion ≈ $601.24 Million |
+10.05% |
| 2018-12-31 | zł1.99 Billion ≈ $546.32 Million |
+3.44% |
| 2017-12-31 | zł1.92 Billion ≈ $528.17 Million |
+0.40% |
| 2016-12-31 | zł1.91 Billion ≈ $526.08 Million |
+5.66% |
| 2015-12-31 | zł1.81 Billion ≈ $497.92 Million |
+0.75% |
| 2014-12-31 | zł1.80 Billion ≈ $494.21 Million |
+2.04% |
| 2013-12-31 | zł1.76 Billion ≈ $484.35 Million |
+8.18% |
| 2012-12-31 | zł1.63 Billion ≈ $447.70 Million |
+6.04% |
| 2011-12-31 | zł1.53 Billion ≈ $422.19 Million |
+3.08% |
| 2010-12-31 | zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more